APP and Alzheimer disease: Given the involvement of the PI3K/mTOR pathway in AD pathogenesis, we sought to evaluate the effects of a 12-week daily oral treatment with PF-04691502 on AD-like pathology of 18-month-old APP/PS1 mice.